Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Fine

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
MDM Policy & Practice|September 20, 2019
Economic Analysis of Hospital Palliative Care: Investigating Heterogeneity by Noncancer DiagnosesPeter May, Charles Normand, Egidio Del Fabbro, et al.
The Journal of Biological Chemistry|July 20, 2007
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistanceRichard D Dinnen, Lisa Drew, Daniel P Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancerJohn A Chabot, Wei-Yann Tsai, Robert L Fine, et al.
International Journal of Oncology|January 13, 2005
BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivoSeong-Hoon Moon, Jin-Chul Heo, Robert L Fine, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2007
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysisRobert L Fine, David R Fogelman, Stephen M Schreibman, et al.
Cancer|February 5, 2008
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomasCasilda Balmaceda, David Peereboom, Susan Pannullo, et al.
Oncology|December 14, 2012
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literatureAnthony P Gulati, Benjamin Krantz, Rebecca A Moss, et al.
Journal of Neuro-Oncology|July 20, 2007
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissueShailendra Joshi, Mei Wang, Joshua J Etu, et al.
Molecular Cancer Therapeutics|October 16, 2013
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDACRichard D Dinnen, Yuehua Mao, Wanglong Qiu, et al.
Surgical Oncology Clinics of North America|September 8, 2004
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTXDavid R Fogelman, Johnson Chen, John A Chabot, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
MDM Policy & Practice|September 20, 2019
Economic Analysis of Hospital Palliative Care: Investigating Heterogeneity by Noncancer DiagnosesPeter May, Charles Normand, Egidio Del Fabbro, et al.
The Journal of Biological Chemistry|July 20, 2007
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistanceRichard D Dinnen, Lisa Drew, Daniel P Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancerJohn A Chabot, Wei-Yann Tsai, Robert L Fine, et al.
International Journal of Oncology|January 13, 2005
BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivoSeong-Hoon Moon, Jin-Chul Heo, Robert L Fine, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2007
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysisRobert L Fine, David R Fogelman, Stephen M Schreibman, et al.
Cancer|February 5, 2008
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomasCasilda Balmaceda, David Peereboom, Susan Pannullo, et al.
Oncology|December 14, 2012
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literatureAnthony P Gulati, Benjamin Krantz, Rebecca A Moss, et al.
Journal of Neuro-Oncology|July 20, 2007
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissueShailendra Joshi, Mei Wang, Joshua J Etu, et al.
Molecular Cancer Therapeutics|October 16, 2013
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDACRichard D Dinnen, Yuehua Mao, Wanglong Qiu, et al.
Surgical Oncology Clinics of North America|September 8, 2004
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTXDavid R Fogelman, Johnson Chen, John A Chabot, et al.
Pageof 7